Capital International Investors Sells 38,900 Shares of Zai Lab Limited (NASDAQ:ZLAB)

Capital International Investors reduced its stake in Zai Lab Limited (NASDAQ:ZLABFree Report) by 4.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 806,453 shares of the company’s stock after selling 38,900 shares during the quarter. Capital International Investors owned approximately 0.82% of Zai Lab worth $22,040,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Bamco Inc. NY lifted its holdings in Zai Lab by 4.5% in the 3rd quarter. Bamco Inc. NY now owns 1,579,349 shares of the company’s stock worth $38,394,000 after purchasing an additional 67,288 shares during the last quarter. Rock Springs Capital Management LP lifted its holdings in shares of Zai Lab by 1.2% during the third quarter. Rock Springs Capital Management LP now owns 1,237,023 shares of the company’s stock worth $30,072,000 after buying an additional 14,600 shares during the last quarter. Clearbridge Investments LLC lifted its holdings in shares of Zai Lab by 1.4% during the third quarter. Clearbridge Investments LLC now owns 822,888 shares of the company’s stock worth $20,004,000 after buying an additional 11,574 shares during the last quarter. Allianz Asset Management GmbH lifted its holdings in shares of Zai Lab by 26.1% during the fourth quarter. Allianz Asset Management GmbH now owns 679,524 shares of the company’s stock worth $18,571,000 after buying an additional 140,461 shares during the last quarter. Finally, Hsbc Holdings PLC lifted its holdings in shares of Zai Lab by 251.1% during the third quarter. Hsbc Holdings PLC now owns 327,781 shares of the company’s stock worth $7,968,000 after buying an additional 234,431 shares during the last quarter. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Zai Lab Stock Performance

Shares of NASDAQ ZLAB opened at $20.00 on Friday. The business has a fifty day simple moving average of $17.26 and a 200 day simple moving average of $21.09. Zai Lab Limited has a one year low of $13.48 and a one year high of $32.60.

Zai Lab (NASDAQ:ZLABGet Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.38. Zai Lab had a negative return on equity of 40.21% and a negative net margin of 116.45%. The firm had revenue of $87.15 million for the quarter, compared to analysts’ expectations of $77.07 million. During the same period in the prior year, the business posted ($0.51) earnings per share. Analysts predict that Zai Lab Limited will post -3.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Citigroup cut their target price on Zai Lab from $123.00 to $66.00 and set a “buy” rating for the company in a research note on Thursday, February 29th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $64.22.

Get Our Latest Analysis on ZLAB

Insider Buying and Selling at Zai Lab

In other Zai Lab news, insider Frazor Titus Edmondson III sold 10,000 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $21.33, for a total value of $213,300.00. Following the sale, the insider now directly owns 16,408 shares in the company, valued at $349,982.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Rafael Amado sold 2,544 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $18.86, for a total transaction of $47,979.84. Following the sale, the insider now owns 20,093 shares in the company, valued at $378,953.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Frazor Titus Edmondson III sold 10,000 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $21.33, for a total value of $213,300.00. Following the sale, the insider now owns 16,408 shares in the company, valued at approximately $349,982.64. The disclosure for this sale can be found here. Insiders have sold 22,568 shares of company stock worth $421,808 over the last three months. Company insiders own 5.23% of the company’s stock.

Zai Lab Company Profile

(Free Report)

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

Read More

Institutional Ownership by Quarter for Zai Lab (NASDAQ:ZLAB)

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.